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a b s t r a c t
Leiomyosarcoma is extremely rare with a reported incidence of 1:350,000. So accurate preoperative
diagnosis of mesenteric soft tissue tumor is generally difﬁcult. Leiomyosarcoma is a malignant tumour
arising from smoothcell lineage. Mesenteric leiomyosarcoma occurs most commonly in middle-aged
individuals. We describe a case of leiomyosarcoma arising from the ileal mesentery in a 33 year old male
patient. The diagnosis was based on histopathologic evaluation using immunohistochemical staining.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Leiomyosarcoma is a malignant mesenchymal tumor that
derives from the smoothmuscle lineage [1]. The underlying genetic
mechanisms remain unclear and complex. Unbalanced karyotypic
defects are the only shared features observed across the differ-
ent leiomyosarcoma subtypes. Cell-cycle perturbations, mainly
through RB1 defects, and phosphatidylinositol 3 kinase/Akt path-
way activation caused by PTEN genomic deletion are the two
most consistent drivers commonly observed in sarcomas, including
leiomyosarcoma [1].
Mesenteric leiomyosarcoma likely derives from the smooth
muscle of blood vessels in themesentery [3], and little information
is available regarding clinical presentation, pathology, treatment
and prognosis. The occurrence of primary mesenteric leiomyosar-
coma is extremely rare and very few cases appear to have been
reported. So accurate preoperative diagnosis of mesenteric tumor
is generally difﬁcult.
2. Presentation of case
A 33 year old male patient presented with diffuse abdominal
pain and difﬁculty in passing stools for the past 3 years . Pain was
diffusedull aching in character,mainly aggravatedduringnight and
relieved on lying in prone position. Later pain shifted to left side of
abdomen. He complains of passing mucous in stools. He has loss
of appetite and early satiety with occasional episodes of nausea for
the past 6 months. No history of malena, fever, vomiting, loss of
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weight . He was treated as a case of irritable bowel syndrome for
past 3 years.
On examination, a well deﬁned ﬁrm tender mass of 10×10 cms
was felt in the left lumbar and umbilical region. Itwas freelymobile
in the direction perpendicular to mesentery, with nodular surface.
Nomovement with respiration and on percussion an impaired res-
onant note was heard. Per rectal examination was with in normal
limits.
Based on the clinical ﬁndings a provisional diagnosis of mesen-
teric mass was made and further investigated.
USG abdomen showed lobulated hypoechoic intra abdominal
mass lesion.GIST,with areasof vascularity. CECTabdomenrevealed
large neoplasm 8.6×9.7×9.0 cms in abdomen related tomesentry
displacing the adjacent intestine. No invasion to adjacent organs.
No metastasis to liver. No enlarged lymph nodes.
Intra operatively there was a large lobulated 15×15 cm tumor
in the small bowel mesentry at the transition zone of jejunum
and ileum without any breach the peritoneal covering. There is no
mesenteric lymphadenopathy, no inﬁltration to bowel, no ascites
and no liver/pelvic/peritoneal metastasis. So resection of tumour
with a segment of small bowel was done (Fig. 1 and 2).
Histopathology came as leiomyosarcoma, FNCLCC grade 3,
involving mesentery, resected small bowel are unremarkable
(Fig. 3 and 4).
Immunohistochemistrywas strongly positive for SMAandCD99
and negative for CD117, CD 34, abd bcl-2 [2]. The mitotic rate was
8/10HPF with atypical mitosis.
3. Discussion
Primary mesenteric leiomyosarcoma in adolescent patients is
exceedingly rare, with little known about its pathology.Mesenteric
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Fig. 1. CECT picture of leiomyosarcoma.
leiomyosarcoma inanadultwasﬁrstdescribedbyYannopoulos and
Stout et al. [3]. The differential diagnosis includes leiomyosarcoma
and other mesenteric tumors such as GIST, malignant myoﬁbrob-
lastic tumor, solitary ﬁbroustumor, liposarcoma, and lymphoma
[2]. Generally, percutaneous biopsy is contraindicated because skin
metastasis andperitoneal disseminationmaybe inducedbybiopsy.
A deﬁnitive diagnosis of leiomyosarcoma can only be made by
histopathologic study, including immunohistochemical staining
and genetic analysis.
Treatment strategies for mesenteric leiomyosarcoma vary. Sur-
gical excisionwith a widemargin of normal tissue is most effective
since adjuvant chemotherapy or radiotherapy are unreliable [4]. In
our case enblock resection was done and the margins were free
from tumor. Lee noted that surgeons should attempt to improve
the survival rate by radical removal of all smooth muscle tumors,
including the removal of at least 4 inches of healthy tissue on all
sides of the tumor, plus the corresponding mesentery [6].
Patientswith leiomyosarcomaof thebowelmesenterygenerally
display a poor prognosis. The overall 5-year survival rate for this
tumor is only 20%–30% [5], and complete primary surgical resection
is critical for achieving the best outcome. Conversely, recurrence
can occur within 5 years, so that close and long term follow-up of
such patients for 5 years or more, with particular attention to the
gastrointestinal tract, liver, and lung, is necessary.
Pathologically, leiomyosarcoma exhibits high mitotic activity.
Survival is inﬂuenced by the histological grade of mesenteric
leiomyosarcomas, based on cell differentiation, cellularity of the
tumor, anaplasia, and number of mitoses per HPF. Ranchod and
Kempsonshowed frequencyofmitoses tobe themostuseful indica-
Fig. 2. Microscopic picture of resected tumour.
tor ofmalignant potential [7]. Simpsonet al. introducedhistological
grading of intestinal leiomyosarcomas [8]. Grade 3 hasmarked cel-
lularity anaplasia, and a mitotic index more than 10 mitoses per
10HPFs. As our histopathology showed FNCLCC grade 3 andmitotic
Fig. 3. Intraoperative picture of tumour.
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Fig. 4. Resected part of the tumour.
rate of 8/10HPF, patient was put on radiotherapy for further man-
agement.
Guidelines for the management of gastrointestinal leiomyosar-
coma ormesenteric leiomyosarcoma are unclear, probably because
of the small number of patients reported. Earlier detection using
ultrasonography and computed tomography, as well as complete
surgical resection, may improve long-term prognosis in patients
with primary leiomyosarcoma of mesenteric origin.
4. Conclusion
Primary mesenteric leiomyosarcoma is a rare entity. Because of
its rarity there is nouniform treatmentmodality for the same.Diag-
nosis can only be conﬁrmed by histopathology and immunological
staining. Even though surgery is the main modality of treatment
recurrence is common with this. Early detection and wide surgical
resection will improve the prognosis of this type of lesion.
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